Mark A. Goldberg, MD

Scientific Officer

Dr. Mark Goldberg, MD, is a medical oncologist and hematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society and American Cancer Society Cancer Action Network volunteer. Dr. Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, Avacta Group PLC, and Blueprint Medicines. Dr. Goldberg previously served on the executive management team of Synageva Biopharma from 2011-2014. Before that, Dr. Goldberg served in various management capacities of increasing responsibility at Genzyme Corporation from 1996-2011, most recently as senior vice president of clinical development. Dr. Goldberg is the past chair of the Eastern New England Area Board and was a member of the former New England Division Board. Dr. Goldberg has served on the American Cancer Society Board of Directors since 2019.